Pterostilbene Menopause Symptoms Randomized Trial: What the Evidence Says

Quick Answer

Pterostilbene Menopause Symptoms Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• The deficiency of E2 in post-menopausal women can lead to osteoporosis, increased risk of cardiovascular disease and increased risk of type 2 diabetes. [Holmes Holly E. (2026); evidence level 2]
• Hot flashes are associated with discomfort, poor sleep, fatigue and a decreased quality of life. [Holmes Holly E. (2026); evidence level 2]
• This structural diversity presents a vast landscape for exploring stilbenes with enhanced potency, improved bioavailability, and targeted therapeutic actions against specific NDs,. [Begh Md. Zamshed Alam (2024); evidence level 3]
• They have been found to exert their beneficial effects through various mechanisms, including antioxidant activity, anti-inflammatory effects, enhancement of neurotrophic factors, protein aggregation inhibition, and modulation of autophagy. [Begh Md. Zamshed Alam (2024); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For pterostilbene menopause symptoms randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Holmes Holly E. (2026). Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial. DOI: 10.3389/fragi.2026.1773667. PMCID: PMC13213337. PMID: 42211736. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13213337/
• Begh Md. Zamshed Alam (2024). Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap. DOI: 10.7150/ijbs.102032. PMCID: PMC11528462. PMID: 39494329. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC11528462/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.